Almirall, S.A.

BME:ALM Rapporto sulle azioni

Cap. di mercato: €1.8b

Almirall Performance dei guadagni passati

Il passato criteri di controllo 0/6

Gli utili di Almirall sono diminuiti a un tasso medio annuo di -64.4%, mentre il settore Pharmaceuticals ha visto gli utili crescere a un tasso medio annuo di 12.9%. I ricavi sono cresciuti crescere a un tasso medio annuo di 1.6%.

Informazioni chiave

-64.4%

Tasso di crescita degli utili

-61.8%

Tasso di crescita dell'EPS

Pharmaceuticals Crescita del settore5.0%
Tasso di crescita dei ricavi1.6%
Rendimento del capitale proprio-3.1%
Margine netto-4.7%
Ultimo aggiornamento sui guadagni30 Sep 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

Almirall, S.A. (BME:ALM) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

Nov 14
Almirall, S.A. (BME:ALM) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

Almirall (BME:ALM) Has A Somewhat Strained Balance Sheet

Nov 06
Almirall (BME:ALM) Has A Somewhat Strained Balance Sheet

Investors Continue Waiting On Sidelines For Almirall, S.A. (BME:ALM)

Sep 07
Investors Continue Waiting On Sidelines For Almirall, S.A. (BME:ALM)

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 90% Above Its Share Price

Jul 12
Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 90% Above Its Share Price

Market Participants Recognise Almirall, S.A.'s (BME:ALM) Revenues

Apr 24
Market Participants Recognise Almirall, S.A.'s (BME:ALM) Revenues

These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Reasonably Well

Mar 20
These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Reasonably Well

Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly

Dec 15
Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly

Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 21% Undervaluation?

Oct 03
Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 21% Undervaluation?

We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt

Aug 24
We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt

Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 31% Undervaluation?

Jul 05
Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 31% Undervaluation?

Is Almirall (BME:ALM) A Risky Investment?

May 16
Is Almirall (BME:ALM) A Risky Investment?

Estimating The Fair Value Of Almirall, S.A. (BME:ALM)

Mar 29
Estimating The Fair Value Of Almirall, S.A. (BME:ALM)

We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt

Jan 04
We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt

An Intrinsic Calculation For Almirall, S.A. (BME:ALM) Suggests It's 29% Undervalued

Dec 01
An Intrinsic Calculation For Almirall, S.A. (BME:ALM) Suggests It's 29% Undervalued

Almirall (BME:ALM) Seems To Use Debt Quite Sensibly

Jul 14
Almirall (BME:ALM) Seems To Use Debt Quite Sensibly

Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly

Mar 23
Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 82% Above Its Share Price

Feb 24
Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 82% Above Its Share Price

Is Almirall (BME:ALM) Using Too Much Debt?

Nov 01
Is Almirall (BME:ALM) Using Too Much Debt?

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 77% Above Its Share Price

Aug 02
Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 77% Above Its Share Price

Is Almirall (BME:ALM) Using Too Much Debt?

Jul 06
Is Almirall (BME:ALM) Using Too Much Debt?

Here's Why Almirall (BME:ALM) Has A Meaningful Debt Burden

Mar 23
Here's Why Almirall (BME:ALM) Has A Meaningful Debt Burden

How Does Almirall, S.A. (BME:ALM) Fare As A Dividend Stock?

Mar 05
How Does Almirall, S.A. (BME:ALM) Fare As A Dividend Stock?

Ripartizione dei ricavi e delle spese

Come Almirall guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

BME:ALM Ricavi, spese e utili (EUR Millions )
DataRicaviGuadagniSpese G+ASpese di R&S
30 Sep 24953-4523712
30 Jun 24932-352200
31 Mar 24915-392143
31 Dec 23899-382090
30 Sep 2390772097
30 Jun 23898-112010
31 Mar 23882-82053
31 Dec 2287942020
30 Sep 22864920724
30 Jun 22856291970
31 Mar 22843-501908
31 Dec 21837-411880
30 Sep 21814-22201-10
30 Jun 21809-111850
31 Mar 2179055188-8
31 Dec 20814741770
30 Sep 2084963167-8
30 Jun 20872861880
31 Mar 209261211880
31 Dec 199111061890
30 Sep 19858852279
30 Jun 19884881820
31 Mar 19789802093
31 Dec 18811781830
30 Sep 18714-111176-10
30 Jun 18730-1791960
31 Mar 18687-293195-6
31 Dec 17677-3042070
30 Sep 17735-1282155
30 Jun 17755-782140
31 Mar 17821732165
31 Dec 16822752130
30 Sep 1677816223010
30 Jun 167431542100
31 Mar 167211112042
31 Dec 157381322010
30 Sep 15783479190-28
30 Jun 158024882440
31 Mar 15842481250-11
31 Dec 148284482740
30 Sep 14868-13262-11
30 Jun 14849-322560
31 Mar 14845-332610
31 Dec 13825-342500

Guadagni di qualità: ALM al momento non è redditizia.

Margine di profitto in crescita: ALM al momento non è redditizia.

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: ALM non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 64.4% all'anno.

Accelerare la crescita: Impossibile confrontare la crescita degli utili di ALM nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia

Guadagni vs Settore: ALM non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Pharmaceuticals ( 8.9% ).

Rendimento del capitale proprio

ROE elevato: ALM ha un Return on Equity negativo ( -3.06% ), in quanto al momento non è redditizio.

Rendimento delle attività

Rendimento del capitale investito

Scoprire le aziende con forti performance passate

7D

1Y

7D

1Y

7D

1Y